XVIVO Perfusion AB (publ) Report on operations 2018

FOURTH QUARTER 2018 (OCT – DEC)

• Total net sales in the quarter amounted to SEK 58.4 (41.6) million, corresponding to an increase of 40 percent in SEK and 33 percent in local currency. Net sales of non-durable goods* in the quarter amounted to SEK 52.3 (39.4) million, corresponding to an increase of 33 percent in SEK and 26 percent in local currency.
• Warm perfusion sales of non-durable goods** showed a record growth of more than 50 percent during the quarter. Sales from warm perfusion represented 50 percent (43) of sales of non-durable goods. 
• Operating income before depreciation and amortization (EBITDA) amounted to SEK 10.5 (8.6) million, corresponding to an EBITDA margin of 18 percent. In comparison the operating income before depreciation and amortization (EBITDA) for the same quarter of 2017, excluding items affecting comparability, amounted to SEK 9.1 million.
• Operating income amounted to SEK 6.1 (4.7) million, after amortization and depreciation of SEK 4.4 (3.8) million. 
• Net income amounted to SEK 4.9 (5.6) million, resulting in earnings per share of SEK 0.19 (0.21).  
• Cash flow from operating activities was SEK 2.4 (7.9) million; mainly affected by higher working capital due to strong sales in the quarter.
• 4 XPS machines were delivered in the quarter.

THE PERIOD 2018 (JAN – DEC)

• Total net sales in the period amounted to SEK 187.9 (148.3) million, corresponding to an increase of 27 percent in SEK and 23 percent in local currency. Net sales of non-durable goods* in the period amounted to SEK 172.7 (141.0) million, corresponding to an increase of 22 percent in SEK and 19 percent in local currency. 
• Sales from warm perfusion** represented 43 percent (35) of sales of non-durable goods. The growth of sales from warm perfusion was about 50 percent for the period.
• Operating income before depreciation and amortization (EBITDA) amounted to SEK 30.9 (22.0) million, corresponding to an EBITDA margin of 16 percent. In comparison for the same period of 2017, the operating income before depreciation and amortization (EBITDA), excluding items affecting comparability, amounted to SEK 24.8 million.  
• Operating income amounted to SEK 14.0 (7.1) million, after amortization and depreciation of SEK 16.9 (14.9) million.
• Net income amounted to SEK 12.7 (6.3) million, resulting in earnings per share of SEK 0.48 (0.25).  
• Cash flow from operating activities was SEK 23.6 (22.2) million.
• SEK 19 million share issue as a result of warrants being exercised. 
• PMA application for STEEN Solution ™ and XPS™ was filed with the FDA. 
• Perfadex® Plus, an upgraded version of Perfadex®, has been launched in Europe and the USA with successful adoption and positive feedback from clinicians and customers. 
• Analysis of the PrimECC®-study showed that the product is safe and showed positive clinical results. 
• United Therapeutics and XVIVO Perfusion executed a collaboration in which United Therapeutics intends to use XVIVO Perfusion’s products in their organ assessment services.
• 8 XPS™ and LS™ were delivered during the period. At the end of the period 49 hospitals had access to either XPS™ or LS™.

CONFERENCE CALL

CEO Magnus Nilsson will present the report in a conference call at 2 p.m. CET on Friday, February 8, 2019. Telephone UK: +44 (0) 3333 0008 04 or USA: +1 631 913 1422, enter code 61837473#. 

February 8, 2019
Gothenburg
XVIVO Perfusion AB (publ)
Magnus Nilsson, CEO 

* The Company’s revenue is segmented in Sales from non-durable goods and sales from durable goods

** STEEN Solution™ and products and services related to XPS™ and LS™.